MMP9

There are 179 papers on MMP9 in aging research: 24 trials and 55 observational studies in people, 66 in animals, 20 in cells, 12 reviews. The newest story, Oct 30, 2026: “Ramelteon reduced nerve-cell loss in a mouse Parkinson’s model”.

Biomarker

179 papers study it25 findings

14 new papers in 30 daysSee all 179 papers on MMP9

“Smoking was associated with high levels of inflammatory biomarkers, particularly MMP-9 (+51%; current vs. never-smokers)”
Absence of significant coronary artery disease does not eliminate smoking-related cardiovascular risk: insights from the PROMISE trialAmerican journal of preventive cardiology2026doi:10.1016/j.ajpc.2026.101740
  • Human trial24
  • Humans55
  • Animals66
  • Cells20
  • In silico1

Interventions

12

Higher-intensity interval cycling

downin humans1upin humans1

1 study
  1. Higher-intensity interval cycling decreases MMP9 in humans (at 90 min after exercise; compared with control changes) (decreased by 114 ng·mL versus control (18 to 211)).

    “Delta MMP-9 then decreased by 114 ng·mL (18 to 211, P = 0.02) 90 min after higher-intensity exercise compared with the changes in control.”

    Human trialat 90 min after exercise; compared with control changes70% peak power output90 minn = 40

    Acute Inflammatory Responses to Exercise in Patients with Abdominal Aortic Aneurysm

    Medicine and science in sports and exercise

  2. Higher-intensity interval cycling increases MMP9 in humans (immediately after exercise; compared with control changes) (+118 ng·mL versus control (95% CI 23 to 214)).

    “Delta MMP-9 showed a 118-ng·mL (95% confidence interval = 23 to 214, P = 0.02) greater increase immediately after higher-intensity exercise compared with changes in control in both groups.”

    Human trialimmediately after exercise; compared with control changes70% peak power outputn = 40

    Acute Inflammatory Responses to Exercise in Patients with Abdominal Aortic Aneurysm

    Medicine and science in sports and exercise

More on Higher-intensity interval cycling

Antihypertensive agents

downin humans1

1 study
  1. Antihypertensive agents are linked with lower MMP9 in humans (controlled hypertensive vs prehypertensive participants) (4.41 ± 0.5 vs 4.74 ± 0.5 ng/mL, p = 0.002).

    “MMP-9 concentrations were significantly higher in the PH group (4.74 ± 0.5 ng/mL) compared to the CHT group (4.41 ± 0.5 ng/mL; p = 0.002).”

    Humanscontrolled hypertensive vs prehypertensive participantsplasma

    Effects of antihypertensive therapy on matrix metalloproteinase-9 levels in controlled hypertensive patients

    BMC cardiovascular disorders

More on Antihypertensive agents

Doxycycline

downin reviews1

1 study
  1. Doxycycline inhibits MMP9.

    “Tetracycline derivatives, particularly sub-antimicrobial dose doxycycline, directly inhibit MMP-9 activity”

    Reviewsub-antimicrobial dose

    Matrix Metalloproteinase-9 (MMP-9) as a Therapeutic Target: Insights into Molecular Pathways and Clinical Applications

    Pharmaceutics

More on Doxycycline

Diet and exercise program

no changein humans1

1 study
  1. Diet and exercise program showed no clear effect on MMP9 in humans.

    “However, there were no statistically significant differences in serum levels of IL-6, MMP-9, TIMP-1, and TIMP-2 since the p was >0.05.”

    Human trial8 weeksn = 11

    Laboratory Assessment of the Effects of AGA@4life Multidisciplinary Intervention on the Inflammatory Profile, MMPs, and TIMPs in a Geriatric Population

    Healthcare (Basel, Switzerland)

More on Diet and exercise program

CD147 inhibition

downin mice1

1 study
  1. CD147 inhibition decreases MMP9 in mice (experimental stroke).

    “Acute inhibition of CD147 decreases levels of MMP-9”

    Animalsexperimental stroke

    EMMPRIN/CD147 plays a detrimental role in clinical and experimental ischemic stroke

    Aging

More on CD147 inhibition

Neural stem cells

downin mice1

1 study
  1. Neural stem cells decrease MMP9 in delayed tPA-treated aged stroke mice.

    “decreased the level of matrix metalloprotease-9 (MMP-9)”

    Animalsin delayed tPA-treated aged stroke micehuman

    Human neural stem cells improve early stage stroke outcome in delayed tissue plasminogen activator-treated aged stroke brains

    Experimental neurology

More on Neural stem cells

Tranexamic acid

downin mice1

1 study
  1. Tranexamic acid decreases MMP9 in mice (natural aging).

    “the blood level of tumor necrosis factor-α, interleukin-6, reactive oxygen species (ROS), and matrix metalloproteinase (MMP)-9 was decreased by tranexamic acid administration”

    Animalsnatural agingblood12 mg/kg/day

    Effect of tranexamic acid in improving the lifespan of naturally aging mice

    Inflammopharmacology

More on Tranexamic acid

Arctic residence

upin humans1

1 study
  1. Arctic residence is linked with higher MMP9 in humans (compared with residents of Western Siberia).

    “The contents of MMP-1, MMP-9, TIMP-1 and TIMP-4 in plasma of northerners were higher compared to those of the residents of Western Siberia (55o N).”

    Humanscompared with residents of Western Siberiablood plasmamales

    Age-related dynamics of the contents of matrix metalloproteinases (MMP-1, -2, -3, -9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, -2, -4) in blood plasma of residents of the European part of the Arctic zone of the Russian Federation

    Advances in gerontology = Uspekhi gerontologii

More on Arctic residence

Urolithin A

downin human cells1

1 study
  1. Urolithin A decreases MMP9 in human cells.

    “decreased matrix metalloproteinas-9 (MMP-9) activity”

    Cells

    Metabolite of ellagitannins, urolithin A induces autophagy and inhibits metastasis in human sw620 colorectal cancer cells

    Molecular carcinogenesis

More on Urolithin A

Resveratrol

downin humans1−48%

1 study
  1. Resveratrol decreases MMP9 in humans (-48%).

    “The level of CSF MMP9 was significantly reduced in the placebo group between baseline and 52 weeks, and MMP9 was further reduced (48%) at 52 weeks in the resveratrol group.”

    Human trial52 weeks

    Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease

    Journal of neuroinflammation

More on Resveratrol

Berberine

downin humans1

1 study
  1. Berberine decreases MMP9 in ACS patients following PCI.

    “Furthermore, the changes in MMP-9, ICAM-1 and VCAM-1 from baseline to after 1 month of treatment differed significantly between the two patient groups.”

    Human trialin ACS patients following PCI300 mg, t.i.d.30 daysn = 130

    Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention

    Clinical and experimental pharmacology & physiology

More on Berberine

All 12

Effects

1

Major adverse cardiovascular events

mediatesin humans1

1 study
  1. MMP9 is linked with major adverse cardiovascular events in humans (Mediation of the smoking–MACE association) (25% mediated for current smoking; 8% for ever-smoking; ≤0.05).

    “MMP-9 (+51%; current vs. never-smokers), which partially mediated the smoking-MACE association (current: 25%; ever: 8%, ≤0.05)”

    HumansMediation of the smoking–MACE association

    Absence of significant coronary artery disease does not eliminate smoking-related cardiovascular risk: insights from the PROMISE trial

    American journal of preventive cardiology

Upstream

2

Peripheral blood

upin humans1

1 study
  1. Peripheral blood is linked with higher MMP9 in humans (serum compared with synovial fluid; TGFβ-2 also elevated).

    “Senescent-associated factor MMP-9 and regenerative factor TGFβ-2 were significantly elevated in serum compared to synovial fluid.”

    Humansserum compared with synovial fluid; TGFβ-2 also elevatedblood serumn = 7

    A Systemic and Local Comparison of Senescence in an Acute Anterior Cruciate Ligament Injury-A Pilot Case Series

    Life (Basel, Switzerland)

Werner syndrome

no changein humans1

1 study
  1. Werner syndrome was not clearly linked with MMP9 in humans (WS: 147.2 ± 28.5 ng/mL; normal adults: 109.1 ± 9.4 ng/mL; normal elderly individuals: 179.9 ± 16.1 ng/mL).

    “The MMP9 level (ng/mL) in WS (147.2 ± 28.5) was not significantly different in comparison with those from age-matched normal adult population”

    Humanscompared with normal adults aged 25–70 years and normal elderly individuals aged 71–100 yearsserumn = 41

    Inflammageing assessed by MMP9 in normal Japanese individuals and the patients with Werner syndrome

    Intractable & rare diseases research

More on Werner syndrome

Associations

9

Cognitive function

downin humans1

1 study
  1. MMP9 is associated with cognitive function in humans (hypertension and/or type 2 diabetes mellitus).

    “Baseline levels of Aβ1−40, MMP-9, and sTWEAK were associated with lower cognitive performance.”

    Humanshypertension and/or type 2 diabetes mellitusserum59.4% womensn = 101

    Circulating MMP-7 is associated with cognitive decline in individuals with vascular risk factors

    Journal of Alzheimer's disease : JAD

Smoking

upin humans1+51%

1 study
  1. Smoking is associated with MMP9 in humans (Current versus never-smokers) (+51%).

    “Smoking was associated with high levels of inflammatory biomarkers, particularly MMP-9 (+51%; current vs. never-smokers)”

    HumansCurrent versus never-smokers

    Absence of significant coronary artery disease does not eliminate smoking-related cardiovascular risk: insights from the PROMISE trial

    American journal of preventive cardiology

More on Smoking

Skin autofluorescence

upin humans1

1 study
  1. Skin autofluorescence is associated with MMP9 in humans (asymptomatic adults) (p = 0.05).

    “skin autofluorescence remained independently associated with MMP-3 (p < 0.001), MMP-9 (p = 0.05), and TIMP-1 (p = 0.049)”

    Humansasymptomatic adultsplasman = 262

    Skin autofluorescence is associated with plasma levels of matrix metalloproteinases in subjects without overt atherosclerosis

    Vascular medicine (London, England)

More on Skin autofluorescence

Kidney transplant function

downin humans1

1 study
  1. MMP9 is associated with kidney transplant function in humans (pre-transplant biomarker levels in patients undergoing kidney transplantation).

    “Higher pre-KT levels tumor necrosis factor receptor superfamily member 6 (FAS) and MMP-9 levels were independently associated with lower KT function one year after KT.”

    Humanspre-transplant biomarker levels in patients undergoing kidney transplantationplasma1 year after kidney transplantation61.4% malesn = 197

    Senescence Biomarkers and Trajectories of Frailty and Physical Function After Kidney Transplantation

    Clinical transplantation

Sarcopenia

upin humans1

1 study
  1. MMP9 is associated with sarcopenia in humans (geriatric patients) (p = 0.026).

    “SARC-F, serum MMP9 and MMP9/TIMP1 ratio were significantly higher in the group with sarcopenia compared to the group without sarcopenia”

    Humansgeriatric patientsserumn = 88

    The relationship between primary sarcopenia and SARC-F, serum MMP9, TIMP1 levels, and MMP9/TIMP1 ratio in the geriatric patients

    European geriatric medicine

More on Sarcopenia

Cholesterol

upin humans1

1 study
  1. MMP9 is associated with cholesterol in humans (long-living individuals; direct correlation with cholesterol and low-density lipoproteins).

    “in LLIs MMP-9 values correlated directly both with cholesterol and with low-density lipoproteins”

    Humanslong-living individuals; direct correlation with cholesterol and low-density lipoproteins

    The Role of Matrix Metalloproteinases (MMP-2 and MMP-9) in Ageing and Longevity: Focus on Sicilian Long-Living Individuals (LLIs)

    Mediators of inflammation

More on Cholesterol

Anti-cytomegalovirus IgG

upin humans1

1 study
  1. Anti-cytomegalovirus IgG is associated with MMP9 in humans (normal aging) (p = 0.0002).

    “Serum MMP-9 was significantly associated with IgG anti-CMV level (p = 0.0002) in normal aging, but not in WS”

    Humansnormal aging

    Aging-associated latent herpes viral infection in normal Japanese individuals and patients with Werner syndrome

    Intractable & rare diseases research

More on Anti-cytomegalovirus IgG

Age

downin humans1

1 study
  1. Age is associated with MMP9 in humans across age groups up to 69 years.

    “The contents of these enzymes tended to decease with age.”

    Humansacross age groups up to 69 yearsblood plasmamales

    Age-related dynamics of the contents of matrix metalloproteinases (MMP-1, -2, -3, -9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, -2, -4) in blood plasma of residents of the European part of the Arctic zone of the Russian Federation

    Advances in gerontology = Uspekhi gerontologii

Chronological age

upin humans1

1 study
  1. Chronological age is associated with MMP9 in humans (normal Japanese individuals).

    “The serum level of MMP9 was elevated significantly (p < 0.001) with normal ageing from both sexes as hsCRP.”

    Humansnormal Japanese individualsserumn = 217

    Inflammageing assessed by MMP9 in normal Japanese individuals and the patients with Werner syndrome

    Intractable & rare diseases research

Funding

1 grant since 2018

US Department of Veterans Affairs

Latest

Dec 2025: 1Jan 2026: 1Feb 2026: 6Mar 2026: 9Apr 2026: 0May 2026: 3Jun 2026: 3Jul 2026: 3Aug 2026: 4Sep 2026: 3Oct 2026: 9Nov 2026: 547 papers in 12 months
Frontiers in Aging Neuroscience

Ramelteon reduced nerve-cell loss in a mouse Parkinson’s model

Experiments in mice with a chemically induced model of Parkinson’s disease found that the drug also improved movement problems.Experiments in mice with a chemically induced model of Parkinson’s disease found that the drug also improved movement problems.

See all 179 papers on MMP9